EGFR and non-small cell lung carcinoma: An in vitro study showed that osimertinib can regress tumors, improve bone remodeling, and increase survival rates in mice with BoM models, suggesting its potential as a treatment for EGFR‐mutated NSCLC patients with BoM.19